100% free Pass4sure VCS-322 Actual Questions and 100% valid test questions.

Basically memorizing our Administration of Veritas Enterprise Vault 12.x Practice test together with success is secured for the VCS-322 test. You might pass the test with excessive marks or the money back. We certainly have fully tested together with verified, valid VCS-322 Practice Questions via actual test to have prepared and gone away VCS-322 test at typically the first attempt. Fundamentally download our VCE Exam Simulator together with practice. You are going to pass the VCS-322 test.

Exam Code: VCS-322 Practice exam 2022 by Killexams.com team
VCS-322 Administration of Veritas Enterprise Vault 12.x

Exam Title : Veritas Certified Specialist (VCS) - Enterprise Vault
Exam ID : VCS-322
Exam Duration : 105 mins
Questions in exam : 75-85
Passing Score : 69%
Exam Center : Pearson VUE
Real Questions : Veritas Enterprise Vault Administration Real Questions
VCE VCE exam : Veritas VCS-322 Certification VCE Practice Test

Overview, Architecture, and Planning
- Explain the technological benefits of Veritas Enterprise Vault 12.x.
- Describe the components of Veritas Enterprise Vault 12.x.
- Identify the differences between Veritas Enterprise Vault 12.x architectures.

Installation and Configuration
- Identify Veritas Enterprise Vault 12.x prerequisites.
- Describe the process for installing, upgrading, and configuring Veritas Enterprise Vault 12.x components.

Technical Administration: Management and Reporting
- Describe the procedure for managing Veritas Enterprise Vault 12.x Vault Site components (including, but not limited to targets and archives).
- Identify and describe how to apply Retention Categories.
- Describe the archiving process (including, but not limited to targeting, synchronization, and archiving tasks).
- Explain the process for managing Indexes.
- Describe the functionality of Veritas Enterprise Vault 12.x Search.
- Describe the process for managing Veritas Enterprise Vault 12.x Policies.
- Describe the process for importing and exporting archives, including PST migration.
- Describe Veritas Enterprise Vault 12.x client functionality (e.g., Outlook Add-In, Office Mail App, IMAP, Vault Cache, and Virtual Vault).
- Describe the maintenance of Veritas Enterprise Vault 12.x storage.
- Describe the process for configuring and managing Classification.
- Describe the purpose and functionality of Discovery Accelerator.

Monitoring, Reporting, and Troubleshooting
- Describe the Veritas Enterprise Vault 12.x reporting and monitoring features.
- Interpret the output from Veritas Enterprise Vault 12.x Reporting Services.
- Verify Veritas Enterprise Vault 12.x is installed and functioning (e.g., running services, archiving).
- Identify Veritas Enterprise Vault 12.x options for monitoring archiving.
- Describe the tools and steps required to troubleshoot Veritas Enterprise Vault 12.x server and client issues.

Backup and Recovery
- Identify which Veritas Enterprise Vault 12.x components require backup.
- Describe how to back up and recover Veritas Enterprise Vault 12.x.

Administration of Veritas Enterprise Vault 12.x
Veritas Administration availability
Killexams : Veritas Administration availability - BingNews https://killexams.com/pass4sure/exam-detail/VCS-322 Search results Killexams : Veritas Administration availability - BingNews https://killexams.com/pass4sure/exam-detail/VCS-322 https://killexams.com/exam_list/Veritas Killexams : Veritas InfoScale Availability 8.0 for UNIX/Linux: Administration

The Veritas InfoScale Availability 8.0 for Unix/Linux: Administration course is designed for IT professionals tasked with installing, deploying, configuring, and maintaining Veritas Cluster Server (VCS) clusters. This course discusses how to use InfoScale Availability to manage applications and databases in high availability environments and Cloud environments. The course is designed to enable you to gain the necessary fundamental and advanced skills that are required to manage a highly available application in a cluster. It also discusses how to deploy InfoScale Availability in the lab environment to practically implement a trial cluster design and deployment.

Tue, 01 Mar 2022 21:38:00 -0600 en-US text/html https://www.veritas.com/services/education-services/training-courses/infoscale-availability-8-0-admin
Killexams : Oracle and Microsoft Announce Availability of Oracle Database Service for Microsoft Azure

Oracle partners with Microsoft to give Azure customers direct, streamlined access to Oracle databases on Oracle Cloud Infrastructure

AUSTIN, Texas and REDMOND, Wash., July 20, 2022 /PRNewswire/ -- Oracle Corp and Microsoft Corp today announced the general availability of Oracle Database Service for Microsoft Azure. With this new offering, Microsoft Azure customers can easily provision, access, and monitor enterprise-grade Oracle Database services in Oracle Cloud Infrastructure (OCI) with a familiar experience. Users can migrate or build new applications on Azure and then connect to high-performance and high-availability managed Oracle Database services such as Autonomous Database running on OCI.

Offering Customers Choice with Azure and OCI Multicloud Capabilities

Over the last two decades, thousands of customers have relied on Microsoft and Oracle software working well together to run their business-critical applications. As customers migrate applications and data to the cloud, they continue to look for joint solutions from their trusted software partners. Since 2019, when Oracle and Microsoft partnered to deliver the Oracle Interconnect for Microsoft Azure, hundreds of organizations have used the secure and private interconnections in 11 global regions.

Microsoft and Oracle are extending this collaboration to further simplify the multicloud experience with Oracle Database Service for Microsoft Azure. Many joint customers, including some of the world's largest corporations such as AT&T, Marriott International, Veritas and SGS, want to choose the best services across cloud providers to optimize performance, scalability, and the ability to accelerate their business modernization efforts. The Oracle Database Service for Microsoft Azure builds upon the core capabilities of the Oracle Interconnect for Azure and enables customers to more easily integrate workloads on Microsoft Azure with Oracle Database services on OCI. There are no charges for using the Oracle Database Service for Microsoft Azure, the Oracle Interconnect for Microsoft Azure or data egress or ingress when moving data between OCI and Azure. Customers will pay only for the other Azure or Oracle services they consume, such as Azure Synapse or Oracle Autonomous Database.

"Microsoft and Oracle have a long history of working together to support the needs of our joint customers, and this partnership is an example of how we offer customer choice and flexibility as they digitally transform with cloud technology. Oracle's decision to select Microsoft as its preferred partner deepens the relationship between our two companies and provides customers with the assurance of working with two industry leaders," said Corey Sanders, corporate vice president, Microsoft Cloud for Industry and Global Expansion.

"There's a well-known myth that you can't run real applications across two clouds. We can now dispel that myth as we give Oracle and Microsoft customers the ability to easily test and demonstrate the value of combining Oracle databases with Azure applications. There is no need for deep skills on either of our platforms or complex configurations—anyone can use the Azure Portal to harness the power of our two clouds together," said Clay Magouyrk, executive vice president, Oracle Cloud Infrastructure.

"Multicloud takes on a whole new meaning with the launch of the Oracle Database Service for Microsoft Azure. This service, designed to provide intuitive, simple access to the Exadata Database Service and Autonomous Database to Azure users in a transparent manner, responds to the critical need of Azure and Oracle customers to apply the benefits of the latest in Oracle Database technology to their Azure workloads. This combined and interactive connection of services across public clouds sets the stage for what a multicloud experience should be, and is a bold statement about where the future of cloud is heading. It should deliver huge benefits for customers, developers, and the cloud services landscape overall," said Carl Olofson, research vice president, Data Management Software, IDC.

Familiar Experience for Azure Users Combined with an Oracle Managed Service

With the new Oracle Database Service for Microsoft Azure, in just a few clicks users can connect their Azure subscriptions to their OCI tenancy. The service automatically configures everything required to link the two cloud environments and federates Azure Active Directory identities, making it easy for Azure customers to use the service. It also provides a familiar dashboard for Oracle Database Services on OCI using Azure terminology and monitoring with Azure Application Insights.

"Many of our mission-critical workloads are running Oracle databases on-premises at massive scale. As we move these workloads to the cloud, Oracle Database Service for Azure enables us to modernize these Oracle databases to services such as Autonomous Database in OCI while leveraging Microsoft Azure for the application tier," said Jeremy Legg, chief technology officer, AT&T. Watch the video.

"Multicloud architectures enable us to choose the best cloud provider for each workload based on capabilities, performance, and price. The OCI and Azure partnership integrates the capabilities of two major cloud providers, including the Oracle Database services in OCI and Azure's application development capabilities," said Naveen Manga, chief technology officer, Marriott International. Watch the video.

"Oracle Database Service for Microsoft Azure has simplified the use of a multicloud environment for data analytics. We were able to easily ingest large volumes of data hosted by Oracle Exadata Database Service on OCI to Azure Data Factory where we are using Azure Synapse for analysis," said Jane Zhu, senior vice president and chief information officer, Corporate Operations, Veritas.

"Oracle Database Service for Microsoft Azure simplifies our multicloud approach. We're going to be able to leverage the best of Oracle databases in Azure, and we are going to be able to keep our infrastructure in Azure. This is a great opportunity to have the best of the two worlds that eases our migration to the cloud and improves the skills of our people in IT," said David Plaza, chief information officer, SGS. Watch the video.

Additional Resources

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle ORCL, please visit us at oracle.com.

About Microsoft

Microsoft (Nasdaq "MSFT" @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

Trademarks

Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

Contact Info

Carolin Bachmann
Oracle PR
+1.415.622.8466
carolin.bachmann@oracle.com

Microsoft Media Relations
WE Communications for Microsoft
+1 425 638 7777
rapidresponse@we-worldwide.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-microsoft-announce-availability-of-oracle-database-service-for-microsoft-azure-301589773.html

SOURCE Oracle

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to Excellerate the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.

Wed, 20 Jul 2022 00:25:00 -0500 text/html https://www.benzinga.com/pressreleases/22/07/n28130951/oracle-and-microsoft-announce-availability-of-oracle-database-service-for-microsoft-azure
Killexams : Veritas Technologies Named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Backup and Recovery Software Solutions for the 17th Time

Veritas Technologies, a leader in multi-cloud data management, today announced it has been named a Leader in the Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions for the 17th time.1 Veritas believes this recognition further validates the company's investment and commitment to delivering a rapid pace of innovation and the most advanced solutions to protect and recover the critical data of the world's largest enterprises.

Enterprises are facing the unparalleled challenge of managing unprecedented data growth across increasingly complex multi-cloud environments, leading to larger attack surfaces and increasing ransomware threats – one of the biggest business risks today. Veritas is uniquely positioned to address this challenge.

Veritas continues to drive innovation as it executes on its vision for delivering Autonomous Data Management, where data is protected invisibly and automatically without sacrificing human oversight. NetBackup 10 is the industry's first cloud-optimized, highly scalable data protection solution that uses AI and automation, enabling IT to shift its focus from day-to-day business operations to driving transformation. Benefits of the solution include:

  • Automated operations: Dynamic cloud autoscaling, intelligent cloud policies, and AI-based anomaly detection help to maximize efficiency and security with minimal oversight.
  • Cloud-native architecture: Veritas' rearchitected NetBackup technology stack integrates new Cloud Scale Technology to provide a unified, cloud-optimized, secure experience across on-premises, hybrid and multi-cloud environments. It combines cloud-native snapshots with elastic deduplication and lifecycle management capabilities to significantly reduce total cost of ownership.
  • Cybersecurity: NetBackup delivers a multi-layered approach to security providing unparalleled ransomware resiliency in the face of an attack, including immutable storage, malware scanning and automated, orchestrated recovery with a single click.
  • Flexibility: NetBackup provides multiple deployment options for customers delivering the flexibility to choose the ideal solution for their unique requirements and use cases. Options include software only, appliances and SaaS solutions.
  • Global reach: Veritas supports large enterprises on a global scale with a strong partner ecosystem, enabling an advanced customer experience across geographies.

Deepak Mohan, executive vice president of products at Veritas, said: "As enterprises continue to advance their multi-cloud strategies, it is now more important than ever that they deploy an Autonomous Data Management solution that automatically finds and protects data, no matter where it lives, all without human involvement to increase efficiency and reduce complexity. Veritas is continuously innovating and executing to transform the future of data management with autonomous, cloud-optimized solutions. We believe that being recognized as a Leader in the Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions further corroborates our strategy and ongoing dedication to protecting our customers' critical data consistently and efficiently across any cloud at any scale."

A complimentary copy of the full 2022 Gartner Magic Quadrant for Enterprise Backup and Recovery Software Solutions report can be found here.

1Previous titles include Magic Quadrant and Datacenter Backup and Recovery Solutions (2020-2019), Magic Quadrant for Enterprise Backup Software and Integrated Appliances (2014-2015), Magic Quadrant for Enterprise Backup/Recovery Software (2011-2013), Enterprise Backup and Restore Magic Quadrant (2001, 2003-2005), Enterprise Backup Vendor Magic Quadrant (1999-2000). From 2005-2015, Veritas Technologies was known as Symantec.

Gartner, Magic Quadrant for Enterprise Backup and Recovery Software Solutions, Michael Hoeck, Nik Simpson, Jerry Rozeman, Jason Donham, 28 July 2022.

Gartner Disclaimer

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

About Veritas

Veritas Technologies is a leader in multi-cloud data management. Over 80,000 customers—including 95% of the Fortune 100–rely on us to help ensure the protection, recoverability, and compliance of their data. Veritas has a reputation for reliability at scale, which delivers the resilience its customers need against the disruptions threatened by cyberattacks, like ransomware. No other vendor is able to match Veritas' ability to execute, with support for 800+ data sources, 100+ operating systems, 1,400+ storage targets, and 60+ clouds through a single, unified approach. Powered by our Cloud Scale Technology, Veritas is delivering today on its strategy for Autonomous Data Management that reduces operational overhead while delivering greater value. Learn more at www.veritas.com. Follow us on Twitter at @veritastechllc.

Veritas and the Veritas Logo are trademarks or registered trademarks of Veritas Technologies LLC or its affiliates in the US and other countries.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to Excellerate the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.

Wed, 03 Aug 2022 03:25:00 -0500 text/html https://www.benzinga.com/pressreleases/22/08/b28334730/veritas-technologies-named-a-leader-in-the-2022-gartner-magic-quadrant-for-enterprise-backup-and-r
Killexams : Offshore News

CorPower Ocean unveiled the CorPower C4, its first commercial scale Wave Energy Converter (WEC) and CorPack clusters, which the company contends will provide the building blocks for utility scale wave farms.Ultimately, the new CorPower C4 device will form part of a four-system wave array, off the coast of Aguçadoura, Portugal, creating a grid-connected wave farms.“This has been a decade-long development, with significant strides in the last few years to industrialise and optimize our wave energy technology," said Patrik Möller, Co-founder & CEO. "Following today’s launch, we aim to propel wave energy into the future green energy mix as a bankable technology through the HiWave-5 Project.”The CorPower C4…

Thu, 04 Aug 2022 12:00:00 -0500 en text/html https://www.marinelink.com/news/maritime/offshore
Killexams : Open Phones, Part 2

More information about

Open Phones, Part 2

556 Views
Program ID:
521827-4
Category:
Call-In
Format:
Call-In
Location:
C-SPAN Studio, Washington, District of Columbia, United States
First Aired:
Jul 21, 2022 | 8:03am EDT | C-SPAN 1

Airing Details

  • Jul 21, 2022 | 8:03am EDT | C-SPAN 1
Thu, 21 Jul 2022 01:58:00 -0500 en-us text/html https://www.c-span.org/video/?521827-4/washington-journal-news-headlines-viewer-calls=&_escaped_fragment_=
Killexams : Evaluating Web-Based Direct-to-Consumer Genetic Tests for Cancer Susceptibility

Falling costs of genetic testing in combination with growing public interest in personal genomics has driven the expansion of direct-to-consumer (DTC) genetic testing. Today’s market encompasses a broad range of offerings, from tests that pair users with wines to tests that reveal serious disease risks.1 This review focuses on one area of the rapidly expanding DTC market—genetic testing for cancer susceptibility. Within this space, DTC offerings vary considerably in size and scope. The narrowest is a test that screens for three specific mutations in two genes and the broadest is a whole-genome sequencing service that analyzes dozens of genes for mutations that could affect cancer risk.

Traditionally, DTC genetic tests were advertised—and sold—to consumers without involving a health care professional; however, in latest years, a new model of testing has come to dominate the market. In this model, tests are advertised to consumers but ordered by licensed physicians.2-5 A number of companies even allow consumers to choose between having tests ordered by their own physician or by a company-provided independent physician.

In both the academic literature and the popular media, there is a lack of clarity about which genetic tests count as DTC offerings.6 This uncertainty, as Hogarth et al7 explain, stems from ambiguity about the meaning of direct-to-consumer, a term that “has been used variously to refer to both advertising and sale of genetic tests.” According to the US National Institutes of Health (NIH), DTC genetic tests “are marketed directly to customers via television, print advertisements, or the Internet, and . . . can be bought online or in stores.”8(p163) Under this expansive definition, tests that are advertised to consumers but ordered by licensed physicians—often referred to as the hybrid model—fall within the ambit of DTC genetic testing.2,5

CONTEXT

  • Key Objective

  • To provide an overview of available direct-to-consumer (DTC) genetic tests for cancer susceptibility and to identify six aspects of the testing process that could affect consumers’ ability to make informed decisions about testing and interpret their results.

  • Knowledge Generated

  • Recent years have seen DTC genetic testing for cancer susceptibility change dramatically. Specifically, a new model now dominates the market where tests are advertised to consumers but ordered by physicians. Moreover, many of today’s tests are distinguished from earlier DTC offerings for cancer susceptibility by their scope and potential clinical significance. This review provides a comprehensive overview of available DTC genetic tests for cancer susceptibility and identifies aspects of the DTC testing process that could affect consumers’ ability to make informed decisions about testing and understand their results. Given how the DTC genetic testing market for cancer susceptibility has changed in latest years, it is essential that health care professionals and researchers working in this space appreciate both the range of tests being offered and the challenges that consumers may face as they navigate this evolving landscape.

  • Relevance

  • On the basis of our review of companies’ Web sites, consumers would benefit from more information about certain aspects of the testing process. Providing this information would help consumers make informed decisions about whether to use a particular DTC genetic testing service and, should they choose to pursue testing, understand the implications and limitations of their results.

Other than the shift toward physician-ordered testing, many of today’s tests are distinguished from their predecessors by their scope and potential clinical significance. Previously, in the mid-to-late 2000s, most DTC tests used single-nucleotide variation profiling to assess cancer risk, a process that involves screening a DNA trial for single-nucleotide polymorphisms (SNPs)—single base-pair differences that occur at specific positions in the genome—that may affect cancer risk.9,10 Single-nucleotide variation profiling, however, tends to have low predictive value for disease risk and limited usefulness in improving health outcomes (ie, clinical utility).

Today’s DTC companies have largely moved away from using single-nucleotide variation profiling. Instead, they tend to analyze specific genes for mutations that increase cancer risk. Yet this change has not eliminated uncertainty in cancer susceptibility genetic testing. For many of the genes included in larger tests, a positive result may be associated with uncertain risk estimates and/or unclear medical management strategies.11,12

Given how the DTC genetic testing market for cancer susceptibility has changed in latest years, it is essential that health care professionals and researchers working in this space appreciate both the range of tests being offered and the challenges that consumers may face as they navigate this evolving landscape. Part I of this paper provides an overview of available DTC genetic tests for cancer susceptibility as of July 2019. For each test, we discuss cost; who orders it; whether variants of uncertain significance (VUS) are returned; availability of genetic counseling; intended users; whether consumers are recontacted about variant reclassifications; whether the test is characterized by the company as being diagnostic, actionable, and clinically valid; molecular technique used to analyze DNA; and whether the test is Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited.

In Part II, we identify six aspects of the testing process that we believe could affect consumers’ ability to make informed decisions about testing and understand the implications—and limitations—of their results.13 These are: how companies use certain terms (eg, medical grade or clinical grade); how companies use consumers’ health information during the ordering process; the extent of genetic counseling provided by companies; companies’ procedures for returning results; the role of company-provided ordering physicians; and companies’ procedures for communicating variant reclassifications. On the basis of our review of companies’ Web sites, we believe that consumers would benefit from more information about these aspects of testing.

Here we describe the array of DTC genetic tests for cancer susceptibility that were on the market as of July 2019 (Table 1). Given the Internet-based nature of DTC genetic testing, today’s consumers primarily receive and interact with DTC companies’ offerings through their Web sites. Thus, to better capture the information that consumers are likely to access when deciding whether to use a test, we only include information about testing services that is, or was, available on companies’ Web sites. It is worth noting that some companies do not explicitly define the terms diagnostic, actionable, or clinically valid. Whereas we describe how each company characterizes these terms and indicate when definitions are absent, inasmuch as our objective is to convey what companies report on their Web sites, we do not evaluate the accuracy of their claims.14

Table

TABLE 1. Direct-to-Consumer Genetic Tests for Cancer Susceptibility

23andMe

In 2013, the US Food and Drug Administration (FDA) issued a warning letter to 23andMe (Sunnyvale, CA) ordering the company to discontinue marketing its Personal Genome Service, which included reports for several hundred diseases and conditions, an SNP-based risk score for breast cancer, and a limited BRCA1/BRCA2 test.15 According to the FDA, 23andMe had failed to demonstrate that its service could correctly identify genetic disease risks, made misleading claims about the health benefits of tests, and failed to comply with the premarket review process for medical devices.16

Since that time, 23andMe has substantially revised its services. In March 2018, the FDA authorized 23andMe to market a BRCA test that screens for three specific BRCA1/BRCA2 variants, making it the first FDA-authorized DTC genetic test to report on cancer risk.17,18 Although there are more than 1,000 known BRCA1/BRCA2 mutations that are associated with an increased risk of breast and ovarian cancer, 23andMe’s test only screens for three founder mutations—two in the BRCA1 gene (BRCA1 c.68_69delAG and BRCA1 c.5266dupC) and one in the BRCA2 gene (BRCA2 c.5946delT)—that are found almost exclusively in individuals of Ashkenazi Jewish descent.17 The test, therefore, is unlikely to be useful to individuals from other ethnic backgrounds.19,20 As 23andMe acknowledges, its BRCA screen is not comprehensive and does not rule out the possibility that an individual carries one of the many BRCA1/BRCA2 mutations not covered by its report.21

In January 2019, 23andMe received FDA clearance to expand its cancer susceptibility testing to report on two MUTYH genetic mutations that are implicated in MUTYH-associated polyposis, an autosomal recessive hereditary colorectal cancer syndrome.22 The two variants that are included in the test—p.Y179C and p.G396D—are the most common pathogenic MUTYH mutations in individuals of northern European descent, although there are more than 100 pathogenic MUTYH variants.23 In the general northern European, Australian, and US population, the heterozygous carrier frequency for a pathogenic MUTYH variant is 1% to 2%.2 Individuals with a single MUTYH mutation are thought to have a slightly increased risk of colorectal cancer relative to the general population lifetime risk—approximately 4%.25-27 In contrast, individuals carrying mutations in both MUTYH alleles have a much higher cumulative risk of colorectal cancer—approximately 80% by age 70.28

23andMe’s BRCA report is included with its Health + Ancestry Service.29 Excluding special offers, the service costs $199. Consumers order their own tests and receive their results through an online account. If a consumer does not wish to view his or her BRCA result, they can opt to exclude it from the report. Although the company does not provide genetic counseling, consumers are encouraged to consult with a genetic counselor before and after testing. 23andMe uses genotyping to analyze DNA. The company states that its BRCA test meets FDA requirements for clinical validity, which it defines as “the degree to which a test accurately identifies or predicts a disease of interest.”30 23andMe maintains that its BRCA test “is not intended to diagnose any disease and does not describe a person’s overall risk of developing any type of cancer.”22 It also maintains that the test is not medically actionable and that “[r]esults should be confirmed in a clinical setting before taking any medical action.”22 All DNA samples are processed in CLIA-certified and CAP-accredited laboratories.

Veritas Genetics

Veritas (Santa Clara, CA) offers a whole-genome sequencing service called myGenome Standard that costs $599. For an additional $1,000, consumers can upgrade to myGenome Premium, which includes more diseases and carrier conditions. myGenome (standard and premium) can be ordered by the consumer’s own provider or, for an additional $129, by an independent physician affiliated with the telegenomics company Genome Medical. When the results are ready, Veritas notifies the consumer and the ordering provider, both of whom can then access the report through Veritas’ Web portal. If interested, consumers can pay an additional $99 to receive their raw data.

For myGenome (standard and premium), pathogenic and likely pathogenic results are reported, and benign, likely benign, and VUS results are not typically returned. Veritas does not state whether it will contact the ordering provider or the consumer about variant reclassifications. Through Genome Medical, Veritas offers a complimentary 30-minute return of results genetic counseling session for clinically actionable findings. Consumers can also pay $299 for Comprehensive Genetic Counseling, which includes access to pretest counseling and a 60-minute post-test session to review results.

According to Veritas, its service is intended to be a screening test for healthy individuals; however, myGenome is not meant to be diagnostic because “there is a chance that some of the variants that are associated with health conditions or disease risk could be missed.”31 As such, the test “should not be used to diagnose a known or suspected heritable disease in [the consumer] or [the consumer’s family].”32 Veritas does not state whether myGenome is a clinically valid test. It does, however, characterize myGenome as providing information that may “affect [the consumer’s] health and [is] actionable, be it with changes in diet and activity level, medical screenings, or enhanced vigilance.”33 Nevertheless, it is not clear that Veritas’ findings, at least by themselves, are intended to inform clinical care.34 This interpretation is supported by the company’s informed consent document, which states that “all variants considered clinically relevant in [the consumer’s] report should be confirmed with secondary testing before changes to [the consumer’s] healthcare are made.”32 Veritas uses next-generation sequencing to analyze DNA. The company’s US laboratory is CLIA certified and CAP accredited.

Invitae Corporation

Invitae (San Francisco, CA) offers a cancer susceptibility panel—Invitae Cancer Screen—that consists of 61 genes associated with 10 types of cancer (breast, colorectal, gastric, ovarian, pancreatic, prostate, renal cell, thyroid, uterine, and cutaneous melanoma). In addition, Invitae offers cancer susceptibility testing as part of its Genetic Health Screen, which consists of a 147-gene panel that also analyzes genes related to cardiac diseases and other inherited conditions. Neither test is intended to be diagnostic; both are considered proactive services that are intended for healthy adults without a strong personal or family history of cancer.

Invitae’s Cancer Screen and Genetic Health Screen cost $250 and $350, respectively, and can be ordered by the consumer’s own provider or by a company-provided physician. The ordering provider is notified via e-mail when the results are ready and receives a written report. Consumers who have their test ordered by an independent physician receive an e-mail when the results are ready, at which time they can review their results and schedule an appointment with one of Invitae’s genetic counselors. Post-test genetic counseling is available at no additional cost.

Invitae uses next-generation sequencing and does not report VUS findings for proactive tests. However, if a VUS is reclassified to likely pathogenic or pathogenic, Invitae will inform the ordering physician and issue an updated report. Invitae does not say whether it will contact the ordering physician and issue an amended report for other variant reclassifications. The company also does not state whether either proactive test is clinically valid, although it does provide links to validation studies.35 Regarding actionability, Invitae maintains that consumers can “take action based on [their] results” and “work with [their] provider to consider: increased or earlier screenings, lifestyle modifications, and early intervention to prevent the onset of disease.”36 Invitae’s laboratory is CLIA certified and CAP accredited.

Color Genomics

Color Genomics (Burlingame, CA) offers a test called Color Extended that analyzes genes related to cancer, cardiac disease, and medication response. The test costs $258.95 and includes 30 cancer predisposition genes associated with eight types of cancer (breast, ovarian, uterine, colorectal, melanoma, pancreatic, stomach, and prostate). Color Extended can be ordered by either the consumer’s own provider or by a company-provided independent physician at no additional charge. If the consumer’s own provider orders the test, the provider can choose whether the results are released to the consumer as soon as they are ready or after a delay. For tests that are ordered by an independent physician, information about the process for returning results is not available on the company’s Web site. Consumers who wish to discuss their results can access complimentary genetic counseling.

Color uses next-generation sequencing and reports VUS findings. If a VUS result is reclassified, Color will attempt to recontact the consumer. The company does not state whether Color Extended is a clinically valid test in its entirety. However, there is a section on the Web site where Color discusses the clinical validity of its tests with respect to certain conditions.37 Color Extended is described as being actionable, meaning that the consumer can “work with [their] healthcare provider to create a personalized screening and prevention plan, designed to reduce [their] risk of developing cancer.”38 Color maintains that its test is not diagnostic because “[p]ositive results do not necessarily mean that [the consumer] [has] that hereditary disorder or that [the consumer] will develop the disorder in [their] lifetime” and “[n]egative results do not eliminate [the consumer’s] risk of developing a disorder, and do not certain that [the consumer] will be healthy or will never develop any of the disorders that Color tests for.”39 Color’s laboratory is CLIA certified and CAP accredited.

Helix

Helix (San Carlos, CA) offers two tests—GenePrism and Prostate Cancer Genetic Risk Score—that evaluate cancer susceptibility. Whereas both tests are sold by Helix, GenePrism is administered by PerkinElmer Genomics, and Prostate Cancer Genetic Risk Score is administered by NorthShore University HealthSystem. The tests can only be ordered by a physician who is affiliated with the relevant partner company.

GenePrism analyzes the 59 genes included in the American College of Medical Genetics and Genomics’ list of actionable genes, of which 26 are associated with an increased risk of cancer.40 The test costs $299.99, including a $30 fee that covers the ordering physician and genetic counseling services. The test is “intended to provide proactive health insights for those who do not have a significant family history associated with the health conditions that it includes.”41 The consumer is notified by e-mail when the results are ready to be accessed through the GenePrism Web site. Helix does not explicitly state whether the test is clinically valid. GenePrism is not a diagnostic test and “is not intended to diagnose any medical conditions” and “will not tell you if you currently have one of the conditions covered by the test, or if you definitely will or will not develop the condition in the future.”41 The test does not report VUS results. Helix describes the test as actionable, which, according to the company, means that “if [the consumer] learn[s] of a genetic risk from the test, [the consumer’s] risk is significantly increased over the general population, and there are actions [the consumer] or [the consumer’s] doctor can take to reduce [the consumer’s] risks based on established medical recommendations.”41 Helix does not explain its procedures for recontacting consumers about variant reclassifications, although the company does maintain that “[r]esults may change as research continues to allow us to better interpret what these and other genes mean for health.”41

Prostate Cancer Genetic Risk Score is an outlier among DTC cancer susceptibility tests. Unlike other tests that focus on single-gene mutations, Helix’s test provides a polygenic risk score based on an analysis of numerous SNPs that affect prostate cancer. The test costs $239.99, which includes a $40.00 fee that covers the ordering physician and genetic counseling services. Helix does not state whether the test is intended for individuals with a personal and/or family history of prostate cancer. Results are returned through secure e-mail. Helix maintains that the test is not a diagnostic product because “[a]n estimate of [the consumer’s] risk does not determine if [the consumer] will or will not get prostate cancer.”42 Helix does not state whether the test is clinically valid or whether results are medically actionable.

Helix uses next-generation sequencing to analyze DNA. For both GenePrism and Prostate Cancer Genetic Risk Score, genetic counseling is available through Genome Medical at no additional charge. Helix’s laboratory is CLIA certified and CAP accredited.

Meaning of Terms

In describing their offerings, several companies use terms that they do not clearly define. For example, Invitae characterizes its proactive tests as medical grade and diagnostic grade. Except to say that its proactive tests “offer the same clinical quality as a diagnostic test,” the company does not explicitly define either of these terms.43 Similarly, Color characterizes its offering as an “affordable clinical-grade test,” but does not specify what the term clinical grade means. Of note, despite describing these tests as medical, diagnostic, or clinical grade, both Invitae and Color maintain that their services are not intended to be diagnostic.39,43 Consumers who are unclear about the meanings of these terms, none of which are scientific or medical designations, may struggle to understand why a test that is marketed as medical-, diagnostic-, or clinical grade should not be used in a diagnostic capacity.

In addition, given that tests are often characterized as being medical, diagnostic, or clinical grade, consumers may wonder whether their results could expose them to potential insurance discrimination. According to the Genetic Nondiscrimination Act (GINA), it is illegal for US health insurance providers to use genetic information, including from DTC tests, to deny coverage or increase premiums. GINA, however, does not apply when an employer has fewer than 15 employees or to other forms of insurance (eg, disability insurance, long-term care insurance, and/or life insurance).44 Although all of the companies seem to provide some information on their Web sites about genetic discrimination, discussions about how consumers’ results could affect their access to different types of insurance is often covered during pretest counseling, which may be lacking in the DTC setting.

Companies could also be more transparent about whether their tests can accurately predict an individual’s risk of developing a particular disease—that is, whether they are clinically valid. Most DTC cancer susceptibility genetic tests analyze an array of genes that encompass a wide range of risk estimates. Whereas some of the genes included in these tests have well-established risk estimates, not all do. For example, Color and Veritas’ tests include the MITF gene.45,46 Although MITF mutations are suspected to increase the risk of melanoma and renal carcinoma, the extent to which a mutation carrier’s risk is elevated remains unclear.45,47 Overall, consumers might benefit from greater clarity about which genes in a test are considered clinically valid. Providing this information in a transparent and accessible manner could help consumers decide whether to pursue a test that may include genes with low predictive value for cancer risk.

Use of Consumers’ Health Information

Companies with testing services that can be ordered by a company-provided physician often ask consumers to answer a set of questions about their personal and family health history; however, it is not always clear how ordering physicians use this information. For example, Veritas maintains that consumers’ responses to these questions “are necessary to sequence [their] DNA and also helps [Veritas] better interpret [their] results.”48 Nevertheless, Veritas does not clarify how this information factors into the ordering process. As consumers consider whether to purchase a test, they may be interested in learning how their health information will be used. In particular, they might want to know whether the physician will follow up to discuss their health history before ordering testing. Consumers might also wonder whether company-provided physicians ever decline to order testing and, if so, for what reasons.

Genetic Counseling

Although all of the companies that offer physician-ordered DTC genetic tests seem to provide genetic counseling in some capacity, the extent, timing, and cost of these services is sometimes unclear. For example, Invitae maintains that “[o]ur team of board-certified genetic counselors is available on demand by phone during business hours to assist you with general questions about genetic testing and your results.”49 What remains unclear (for Invitae and some of the other companies) is the extent to which pretest counseling is comprehensive and individualized. In the clinical setting, pretest counseling is widely regarded as an important part of obtaining informed consent to testing.50,51 Companies could therefore help consumers make informed choices about whether to pursue DTC testing by including more information on their Web sites about pretest counseling.

Currently, companies differ in terms of how they provide genetic counseling. Helix, for example, outsources its genetic counseling to Genome Medical, which is a distinct corporate entity from Helix.41 Other companies, such as Invitae, offer in-house counseling that includes pretest counseling.49 This arrangement raises potential ethical concerns about whether a conflict of interest arises when companies provide pretest counseling services for their own tests.52,53

Procedures for Returning Results

Most of the companies that offer tests through the physician-ordered model do not include a detailed description of their process for returning results. On the basis of the companies’ online materials, it may not be clear whether procedures vary depending on the clinical significance of consumers’ results. Are positive and VUS results disclosed over the phone by a genetic counselor, while negative results are delivered through an online portal? Again, providing more information could help consumers make informed decisions about whether they are comfortable with a company’s model for returning results.

Role of Company-Provided Physicians

For some of the companies that offer company-provided independent physicians, it is unclear what role, if any, these physicians play beyond simply ordering tests. It is also not clear how companies conceive of the relationship between consumers and these physicians, some of whom may belong to an external physician network or separate company.54 For example, Helix states that the company “will share [the consumer’s] contact information and health history with PerkinElmer Genomics so a physician they designate can review and make sure this product is right for [the consumer].”41 Consumers may wonder whether they can contact the ordering physician with additional questions about the test or their results. Notably, will the ordering physician assume responsibility for a consumer’s follow-up care or refer the consumer to another provider? As of now, these questions are not easily answerable from companies’ online materials.

Variant Reclassification

As scientific understanding of variant pathogenicity evolves, genetic test results may be amended. Some changes could have significant clinical implications for disease risk and medical management (eg, a VUS that is upgraded to pathogenic). Nevertheless, information about companies’ procedures for handling amended results may not be readily available. Color’s Informed Consent, for instance, lacks specific information about how the company manages variant reclassification beyond stating that it may “at its sole discretion, amend or modify [the consumer’s] Test report” and will “attempt to notify (the consumer) of any material amendments or modifications.”39 Some companies, however, do not provide any information about variant reclassification. Helix’s informed consent, for instance, notes that “future information may change your results,” but does not specify whether the company monitors for variant changes or notify consumers about them.55 Given the potential clinical significance of variant reclassifications, consumers could benefit from more information about companies’ procedures for tracking variant changes and sharing amended results.

In conclusion, genetic testing for cancer susceptibility, once limited to the clinical setting, is now widely available through Web-based DTC genetic testing companies. To better understand whether test takers are knowledgeable about companies’ testing procedures, there is an urgent need to collect and study consumer outcome data.13 As the DTC market continues to evolve, outcome data should inform companies’ products and practices to ensure that consumers are equipped to make informed decisions throughout the testing process and understand their results.

1. Vinome: Home. https://vinome.com/ Google Scholar 2. Allyse MA, Robinson DH, Ferber MJ, et al: Direct-to-consumer testing 2.0: Emerging models of direct-to-consumer genetic testing. Mayo Clin Proc 93:113-120, 2018 Crossref, MedlineGoogle Scholar 3. Roberts JS, Ostergren J: Direct-to-consumer genetic testing and personal genomics services: A review of latest empirical studies. Curr Genet Med Rep 1:182-200, 2013 Crossref, MedlineGoogle Scholar 4. Howard HC, Borry P: Is there a doctor in the house?: The presence of physicians in the direct-to-consumer genetic testing context. J Community Genet 3:105-112, 2012 Crossref, MedlineGoogle Scholar 5. Phillips KA, Trosman JR, Douglas MP: Emergence of hybrid models of genetic testing beyond direct-to-consumer or traditional labs. JAMA 321:2403-2404, 2019 Crossref, MedlineGoogle Scholar 6. Chokoshvili D, Vears DF, Borry P: Growing complexity of (expanded) carrier screening: Direct-to-consumer, physician-mediated, and clinic-based offers. Best Pract Res Clin Obstet Gynaecol 44:57-67, 2017 Crossref, MedlineGoogle Scholar 7. Hogarth S, Javitt G, Melzer D: The current landscape for direct-to-consumer genetic testing: Legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 9:161-182, 2008 Crossref, MedlineGoogle Scholar 8. National Institutes of Health: Genetics Home Reference: What is direct-to-consumer genetic testing? https://ghr.nlm.nih.gov/primer/dtcgenetictesting/directtoconsumer Google Scholar 9. Bellcross CA, Page PZ, Meaney-Delman D: Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J 18:293-302, 2012 Crossref, MedlineGoogle Scholar 10. Kutz G: Direct-to-consumer genetic tests: Misleading test results are further complicated by deceptive marketing and other questionable practices. Washington DC, US Government Accountability Office, 2010 Google Scholar 11. Domchek SM, Bradbury A, Garber JE, et al: Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net? J Clin Oncol 31:1267-1270, 2013 LinkGoogle Scholar 12. Kilbride MK, Domchek SM, Bradbury AR: Ethical implications of direct-to-consumer hereditary cancer tests. JAMA Oncol 4:1327-1328, 2018 Crossref, MedlineGoogle Scholar 13. Spector-Bagdady K: Reconceptualizing consent for direct-to-consumer health services. Am J Law Med 41:568-616, 2015 Crossref, MedlineGoogle Scholar 14. US Food and Drug Administration: Frequently asked questions about CDER. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/frequently-asked-questions-about-cder#4 Google Scholar 15. 23andMe: What you can expect. https://web.archive.org/web/20131127233338/https://www.23andme.com/health/all/ Google Scholar 16. US Food and Drug Administration: Warning letter. https://wayback.archive-it.org/7993/20170111084101/http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm Google Scholar 17. US Food and Drug Administration: FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm599560.htm Google Scholar 18. Francke U, Dijamco C, Kiefer AK, et al: Dealing with the unexpected: Consumer responses to direct-access BRCA mutation testing. PeerJ 1:e8, 2013 Crossref, MedlineGoogle Scholar 19. Gill J, Obley AJ, Prasad V: Direct-to-consumer genetic testing: The implications of the US FDA’s first marketing authorization for BRCA mutation testing. JAMA 319:2377-2378, 2018 Crossref, MedlineGoogle Scholar 20. Artin MG, Stiles D, Kiryluk K, et al: Cases in precision medicine: When patients present with direct-to-consumer genetic test results. Ann Intern Med 170:643-650, 2019 Crossref, MedlineGoogle Scholar 21. 23andMe: Do you speak BRCA? https://www.23andme.com/brca/ Google Scholar 22. 23andMe: 23andMe receives FDA clearance for genetic health risk report that looks at a hereditary colorectal cancer syndrome. https://blog.23andme.com/health-traits/23andme-receives-fda-clearance-for-genetic-health-risk-report-that-looks-at-a-hereditary-colorectal-cancer-syndrome/ Google Scholar 23. US Food and Drug Administration: 510(k) substantial equivalence determination decision summary. https://www.accessdata.fda.gov/cdrh_docs/reviews/K182784.pdf Google Scholar 24. National Institutes of Health: Polyposis MUTYH. https://www.ncbi.nlm.nih.gov/books/NBK107219/#maps.Prevalence Google Scholar 25. National Cancer Institute: Cancer stat facts: Colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html Google Scholar 26. Sampson JR, Jones N: MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol 23:209-218, 2009 Crossref, MedlineGoogle Scholar 27. Win AK, Dowty JG, Cleary SP, et al: Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146:1208-1211.e1201-1205, 2014 Crossref, MedlineGoogle Scholar 28. Win AK, Cleary SP, Dowty JG, et al: Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129:2256-2262, 2011 Crossref, MedlineGoogle Scholar 29. 23andMe: Health + ancestry. https://www.23andme.com/dna-health-ancestry/ Google Scholar 30. 23andMe: Understanding our scientific process. https://medical.23andme.com/about-our-test/ Google Scholar 31. Veritas Genetics: Test limitations. https://www.veritasgenetics.com/sites/default/files/media/documents/ProductOnePager_myGenome_TestLimitations_Final.pdf Google Scholar 32. Veritas Genetics: Informed consent form. https://www.veritasgenetics.com/sites/default/files/media/documents/mg.icP_.1018v4.1.pdf Google Scholar 33. Veritas Genetics: Get the most comprehensive genetic testing service there is. https://www.veritasgenetics.com/myGenome Google Scholar 34. Veritas: myGenome: Frequently asked questions. https://www.veritasgenetics.com/sites/default/files/media/documents/ProductOnePager_myGenome_FAQs_V1_12.04.18.pdf Google Scholar 35. Invitae: Leading with science. https://www.invitae.com/en/validation-studies/ Google Scholar 36. Invitae: Proactive genetic testing. https://www.invitae.com/en/individuals/proactive-testing/ Google Scholar 37. Color: Testing for CDC tier 1 genomic conditions. https://cdn2.hubspot.net/hubfs/3989189/Color%20Population%20Health%20Dossier.pdf?__hssc=19492199.1.1544137941126&__hstc=19492199.dd083e937d69ddfe9539ad39e60ac673.1540603747733.1544130266596.1544137941126.39&__hsfp=3043820372&hsCtaTracking=dd024757-074d-4e51-93aa-6d28feadbb0e%7C99b388e1-993b-43e9-9f98-48687160dff3 Google Scholar 38. Color: Hereditary cancer. https://www.color.com/learn/can-cancer-be-inherited Google Scholar 39. Color: Informed consent. https://www.color.com/informed-consent Google Scholar 40. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 19:249-255, 2017 Crossref, MedlineGoogle Scholar 41. Helix: GenePrism: Actionable insights. https://www.helix.com/products/geneprism-actionable-insights Google Scholar 42. Helix. Prostate cancer genetic risk score. https://www.helix.com/products/prostate-cancer-genetic-risk-score Google Scholar 43. Invitae: How is this type of testing different from a diagnostic genetic test? https://support.invitae.com/hc/en-us/articles/115007883908-How-is-this-type-of-testing-different-from-a-diagnostic-genetic-test- Google Scholar 44. National Institutes of Health: Can the results of direct-to-consumer genetic testing affect my ability to get insurance? https://ghr.nlm.nih.gov/primer/dtcgenetictesting/dtcinsurancerisk Google Scholar 45. Color; MITF. https://static.getcolor.com/pdfs/gene/Color_MITF_gene_information.pdf Google Scholar 46. Veritas: myGenome standard/premium gene-disease list. https://www.veritasgenetics.com/sites/default/files/media/documents/VG_myGenome_Gene-Disease-List_V1_FINAL_Consumer_05.13.2019.pdf Google Scholar 47. Bertolotto C, Lesueur F, Giuliano S, et al: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480:94-98, 2011 [Erratum: Nature 531:126, 2016] Crossref, MedlineGoogle Scholar 48. Veritas: Let’s get started. https://secure.veritasgenetics.com/checkout/67308 Google Scholar 49. Invitae: Genetic counseling resources at Invitae. https://www.invitae.com/en/individuals/genetic-counseling/ Google Scholar 50. American Society of Clinical Oncology: Genetic counseling: An indispensable step in the genetic testing process. J Oncol Pract 4:96-98, 2008 LinkGoogle Scholar 51. American Society of Clinical Oncology: ASCO releases updated policy statement on genetic and genomic testing for cancer susceptibility. https://www.asco.org/about-asco/press-center/news-releases/asco-releases-updated-policy-statement-genetic-and-genomic Google Scholar 52. Pollack A: The ethics of advice: Conflicts seen when genetic counselors work for test companies. The New York Times 2012;B1 Google Scholar 53. Committee on Ethics, American College of Obstetricians and Gynecologists and Committee on Genetics, American College of Obstetricians and Gynecologists: ACOG committee opinion No. 410: Ethical issues in genetic testing. Obstet Gynecol 111:1495-1502, 2008 Crossref, MedlineGoogle Scholar 54. Marietta C, McGuire AL: Currents in contemporary ethics. Direct-to-consumer genetic testing: Is it the practice of medicine? J Law Med Ethics 37:369-374, 2009 Crossref, MedlineGoogle Scholar 55. Helix: PerkinElmer GenePrism: Actionable insights informed consent. https://geneprism.helix.com/product-consent Google Scholar
Fri, 14 Aug 2020 17:22:00 -0500 en text/html https://ascopubs.org/doi/full/10.1200/PO.19.00317
Killexams : FBI, Verizon collaborate on $400M IT overhaul

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may Excellerate our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may Excellerate our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may Excellerate our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Tue, 19 Jul 2022 08:17:00 -0500 en text/html https://washingtontechnology.com/contracts/2022/07/fbi-verizon-collaborate-400m-it-overhaul/374660/
Killexams : A conversation with the Maritime and Port Authority of Singapore (MPA)

For the transport sector to reach net zero, the global shipping industry must keep pace

Founded in 1996, the mission of the Maritime and Port Authority of Singapore (MPA) is to develop Singapore as a premier global port hub and a leading international maritime centre, and to advance and safeguard Singapore’s strategic maritime interests.

Global shipping now contributes to around 2.89% of global emissions, according to the International Maritime Organization’s (IMO) Fourth Greenhouse Gas Study1. These emissions add to the greenhouse effect and many countries in the Asia-Pacific region are already starting to experience the adverse effects of climate change. In 2001, major flooding was caused along the south eastern Malaysia Peninsular when Typhoon Vamei, the first recorded cyclone in the region, hit near the equator. As global warming continues, rising sea levels are threatening vital infrastructure and communities – including Singapore. To offset the worst potential effects of climate catastrophe, the IMO has set a clear target of reducing the shipping industry’s GHG emissions by at least 50% by 2050.

As the world’s largest bunkering port and a major transhipment hub, Singapore has an important role to play in the decarbonisation of the shipping sector. MPA will continue to support this agenda by enabling a multi-fuel transition and believes that the key to accelerating the development of low-carbon fuels is through collaboration between stakeholders.

Pioneering the next fleet of sustainable ports and vessels

A decade ago, MPA became the world’s first maritime administration to launch a comprehensive pro-environment initiative. The Maritime Singapore Green Initiative (MSGI) aimed to promote clean and green shipping in Singapore, and since its inception, the programme has been reviewed and enhanced twice to ensure it is up to date with the latest in climate technology and risk.

Singapore is located at the cross-roads of the East-West trade and sits within the seven-hour flight radius to many emerging Asian markets. MPA capitalises on this strategic location by encouraging green development through five key programmes, which has achieved considerable results to date:

1.  The Green Port Programme (GPP) encourages ships to use cleaner fuels in Singapore through a reduction in port dues. As at 2019, the GPP has also achieved considerable success, with more than 4,700 vessel calls having switched to marine fuel with sulphur content not exceeding 1%. Between January 2020 to December 2021, over 700 vessel calls have benefited from the enhanced MSGI programme.

2. The Green Ship Programme (GSP) incentivises green ship design beyond IMO’s requirements through tax rebates. As at 2020, more than 600 Singapore-flagged ships have qualified for GSP.

3. MPA launched Maritime Greenfuture Fund (GFF) in 2020. The S$40 million fund seeks to accelerate efforts in the development and commercialisation of technologies supporting maritime decarbonisation. A total co-funding of some S$9 million was set aside under the GFF to support up to 3 harbour craft electrification projects. In 2021, MPA and SMI jointly awarded funding from the GFF to three consortiums led by Keppel FELS Limited, SeaTech Solutions and Sembcorp Marine, (comprising a total of 30 enterprises and research institutions) to research, design, build and operate a fully electric harbour craft over the next five years.

4. The Green Energy and Technology Programme (GETP) promotes pilot trials and technology development for maritime emissions reduction. Currently, the annual CO2 emission from the improved ships has been reduced by more than 177,000 tonnes.

5. The Green Awareness Programme (GAP) promotes awareness of sustainability reporting among maritime companies.

MPA understands that the journey to a more sustainable future will not be achieved in silos and is actively partnering with key stakeholders across the shipping industry to Excellerate the pace of change.

Recently, MPA’s MINT fund supported local SME, Billion Miles, and their test bedding partners to develop a novel bio-fuel methanol direct injection system. This class-approved novel design allows for a single injection for both fuel types, hence reducing the complexities of engine design and subsequent expected maintenance costs. 


Greener leadership

As a sector in which industry captains have strong leadership roles in charting the industry path, MPA, together with the Singapore Maritime Foundation set up an International Advisory Panel on Maritime Decarbonisation. The panel provided industry perspectives and recommendations to allow Singapore to support global maritime decarbonisation objectives and to create new opportunities for the industry. A mix of local and international C-suite leaders represent a cross-section of the maritime industry and academia provide their expert guidance and recommendations on how to decarbonise Maritime Singapore. Following the panel’s recommendation in April 2021, MPA announced the formation of the Global Centre for Maritime Decarbonisation (GCMD) in Singapore and its leadership team with effect from 1 August 2021.

The centre was set to spearhead the maritime industry’s energy transition journey with a S$120 million fund from MPA and six founding partners namely BHP, BW Group, Eastern Pacific Shipping, Foundation Det Norske Veritas, Ocean Network Express and Sembcorp Marine. GCMD aims to collaborate with the industry to help the maritime sector reduce GHG emissions, implement identified decarbonisation pathways and create new business opportunities.

Singapore will continue to grow as a sustainable global hub port and support the decarbonisation of international shipping. A multi-fuel transition will be achieved by providing regulatory sandboxes to support trials of alternate fuels, and in line with the whole-of-government approach on decarbonisation, scale up bunkering infrastructure to offer multiple zero/low-carbon fuel solutions.

The backbone of global trade

Marine insurance is a key enabler of global trade and provides the shipping sector with the assurance that it needs to allow commerce to function. The availability of new insurance products can influence decision making by injecting greater confidence among investors to pursue new areas of developments, such as electric vessels.

Lloyd’s has been underwriting marine insurance business for over 330 years and remains a leading market for this class globally.  In 1999, Lloyd’s Asia was established in Singapore and has grown to become Lloyd’s largest underwriting platform, playing an important role in promoting Singapore’s development as a hub for maritime services and insurance. In addition to its substantial business presence, Lloyd’s Asia also collaborates with marine and shipping associations and government agencies in Singapore to enhance the understanding of risk management and marine insurance, including with the MPA which has played an important role in enabling the establishment and growth of Lloyd’s Asia’s marine underwriting capabilities.

MPA is actively bringing organisations together in joint projects to catalyse and co-create maritime decarbonisation solutions across the value chain. They also welcome increased engagement from marine insurers to work with Singapore’s shipping industry. Lloyd’s, MPA and Lloyd’s Singapore underwriters plan to collaborate on marine decarbonisation research to further support the sector. By working together, MPA believes that we can increase momentum in green shipping, achieving a united approach towards decarbonisation.

Marine innovation can help the sector with its transition to a greener future

Maritime decarbonisation is a global challenge requiring a concerted effort from all stakeholders across the value chain, and MPA believes the industry will need to explore multiple decarbonisation pathways to achieve this. To outline Singapore’s long-term strategies for a sustainable maritime industry, MPA has developed the Maritime Singapore Decarbonisation Blueprint 2050 in partnership with industry stakeholders to chart out decarbonisation strategies.

Internationally, Singapore will advance strong and credible climate action, by facilitating partnerships to develop pragmatic solutions. Today, Liquefied Natural Gas (LNG) as a marine fuel remains a key and immediate mean for the maritime industry to reduce its carbon emissions during this low-carbon transition.

As the world’s premier maritime hub, Singapore will continue its role as a global leader in the maritime decarbonisation space, paving the way for the broader industry. As Singapore continues its transition towards a low-carbon future, building on its experience with establishing LNG bunkering, MPA will play a pivotal role in setting up further trials and pilots, with the aim of developing other commercially viable and even greener fuel solutions.

Using the experiences gained through its varied initiatives, Singapore will also support global collaboration in wider critical areas such as regulation, international networks, and the scaling-up of supply chains, to support the industry’s transition into a low-carbon future. The Lloyd’s market will continue to support Singapore, MPA and the Asia-Pacific region with the insurance products needed to support the transition.

1 International Maritime Organization’s (IMO) Fourth Greenhouse Gas Study - Fourth Greenhouse Gas Study

Sun, 03 Apr 2022 05:30:00 -0500 en text/html https://www.lloyds.com/news-and-insights/futureset/join-the-reset/greener-transport/mpa-case-study/
Killexams : AKWEL: STABLE TURNOVER FIGURES FOR THE 1st HALF OF 2022

Akwel

Thursday 28 July 2022

STABLE TURNOVER FIGURES FOR THE 1st HALF OF 2022

  • 5% like-for-like increase

  • Outperformed the global market

  • Sharp decline in current operating income expected over the 2022 financial year

AKWEL (FR0000053027, AKW, PEA-eligible), the automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, has posted consolidated turnover of €488.1m in the first half of 2022, stable compared with the first half of 2021.

Consolidated turnover (1 January to 30 June 2022)

In € millions - unaudited

2022

2021

Variation

Like-for-like variation (1)

1st quarter

245.8

273.3

-10.1%

-4.4%

2nd quarter

242.3

214.3

+13.1%

+16.9%

1st half-year

488.1

487.6

+0.1%

+5.0%

A MORE DYNAMIC SECOND QUARTER

In a context still negatively affected by supply problems in raw materials and electronic components and by international geopolitical tensions, AKWEL recorded a higher level of activity in the second quarter of 2022, with a reported turnover up 13.1%. On a like-for-like basis, the increase was 16.9%, driven in particular by strong growth in North America. The currency impact over the period was -€8.3m, including -€17.3m on the Turkish lira and +€8.5m on the US dollar.

The second-quarter performance resulted in stable reported half-year turnover, up 5% on a like-for-like basis, outperforming the global vehicle production market over the first half of the year (-1.8%1).

BREAKDOWN OF TURNOVER

The geographical breakdown of turnover by production zone was as follows during the six-month period:

  • France: €136.8m (-1.5%)

  • Europe (excluding France) and Africa: €135.8m (-11.4%)

  • North America: €144.2m (+18.4%)

  • Asia and the Middle East (including Turkey): €68.4m (-2.7%)

  • South America: €2.9m (-10.0%)

Products and Functions turnover was up by 1.3% in the first half at €473.2m. The Cooling (+8.3%) and Air (+2.2%) activities continued to grow, driven by market share gains. The Depollution product line limited its decline to -2.6%, and the Aftermarket activities remained strong on SCR tanks. Tooling turnover was down at €11.0m after unusual prior financial years.

NET CASH POSITION OF €116m

The Group generated €7.7m in free cash flow during the first half of 2022, reaching a net cash position as of 30 June, excluding rental obligations, of €116m after the dividend payout.

2022 OUTLOOK

In a global automotive market that continues to be very turbulent, AKWEL confirms its expectation of moderate growth in turnover for the 2022 financial year. However, as mentioned in latest communications, the supply difficulties disrupting the activities of vehicle and equipment manufacturers, particularly at European sites, and the significant inflation observed in the costs of raw materials, components, energy, transport, and labour will have a major impact on the Group’s operating profitability this year. These various increases cannot be easily passed on to sales prices. In all cases, this requires long negotiation periods. This time lag leads AKWEL to anticipate a significant decrease in its current operating income in both the first half and second half of 2022.

Next press release: 2022 half-year results, Thursday 22 September 2022, after the markets close.

An independent, family-owned group listed on the Euronext Paris Stock Exchange, AKWEL is an automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, offering first-rate industrial and technological expertise in applying and processing materials (plastics, rubber, metal) and mechatronic integration.

Operating in 20 countries across every continent, AKWEL employs 9,700 people worldwide.

Euronext Paris – Compartment B – ISIN: FR0000053027 – Reuters: AKW.PA – Bloomberg: AKW:FP

Contacts

AKWEL
Grégory Voisin – Financial VP – Tel.: +33 4 50 56 99 25

EKNO – Press Relations
Christine Savoie – Jean-Marc Atlan – jean-marc.atlan@ekno.fr – Tel.: +33 6 70 08 11 09 / +33 6 07 37 20 44

CALYPTUS – Investor Relations
Mathieu Calleux – akwel@calyptus.net – Tel.: +33 1 53 65 68 68

1 Source: S&P Global Mobility

Attachment

Thu, 28 Jul 2022 03:49:00 -0500 en-US text/html https://www.yahoo.com/now/akwel-stable-turnover-figures-1st-154500206.html
Killexams : Oracle and Microsoft Announce Availability of Oracle Database Service for Microsoft Azure

Oracle partners with Microsoft to give Azure customers direct, streamlined access to Oracle databases on Oracle Cloud Infrastructure

AUSTIN, Texas and REDMOND, Wash., July 20, 2022 /PRNewswire/ -- Oracle Corp and Microsoft Corp today announced the general availability of Oracle Database Service for Microsoft Azure. With this new offering, Microsoft Azure customers can easily provision, access, and monitor enterprise-grade Oracle Database services in Oracle Cloud Infrastructure (OCI) with a familiar experience. Users can migrate or build new applications on Azure and then connect to high-performance and high-availability managed Oracle Database services such as Autonomous Database running on OCI.

Oracle Database Service for Microsoft Azure

Offering Customers Choice with Azure and OCI Multicloud Capabilities

Over the last two decades, thousands of customers have relied on Microsoft and Oracle software working well together to run their business-critical applications. As customers migrate applications and data to the cloud, they continue to look for joint solutions from their trusted software partners. Since 2019, when Oracle and Microsoft partnered to deliver the Oracle Interconnect for Microsoft Azure, hundreds of organizations have used the secure and private interconnections in 11 global regions.

Microsoft and Oracle are extending this collaboration to further simplify the multicloud experience with Oracle Database Service for Microsoft Azure. Many joint customers, including some of the world's largest corporations such as AT&T, Marriott International, Veritas and SGS, want to choose the best services across cloud providers to optimize performance, scalability, and the ability to accelerate their business modernization efforts. The Oracle Database Service for Microsoft Azure builds upon the core capabilities of the Oracle Interconnect for Azure and enables customers to more easily integrate workloads on Microsoft Azure with Oracle Database services on OCI. There are no charges for using the Oracle Database Service for Microsoft Azure, the Oracle Interconnect for Microsoft Azure or data egress or ingress when moving data between OCI and Azure. Customers will pay only for the other Azure or Oracle services they consume, such as Azure Synapse or Oracle Autonomous Database.

"Microsoft and Oracle have a long history of working together to support the needs of our joint customers, and this partnership is an example of how we offer customer choice and flexibility as they digitally transform with cloud technology. Oracle's decision to select Microsoft as its preferred partner deepens the relationship between our two companies and provides customers with the assurance of working with two industry leaders," said Corey Sanders, corporate vice president, Microsoft Cloud for Industry and Global Expansion.

"There's a well-known myth that you can't run real applications across two clouds. We can now dispel that myth as we give Oracle and Microsoft customers the ability to easily test and demonstrate the value of combining Oracle databases with Azure applications. There is no need for deep skills on either of our platforms or complex configurations—anyone can use the Azure Portal to harness the power of our two clouds together," said Clay Magouyrk, executive vice president, Oracle Cloud Infrastructure.

"Multicloud takes on a whole new meaning with the launch of the Oracle Database Service for Microsoft Azure. This service, designed to provide intuitive, simple access to the Exadata Database Service and Autonomous Database to Azure users in a transparent manner, responds to the critical need of Azure and Oracle customers to apply the benefits of the latest in Oracle Database technology to their Azure workloads. This combined and interactive connection of services across public clouds sets the stage for what a multicloud experience should be, and is a bold statement about where the future of cloud is heading. It should deliver huge benefits for customers, developers, and the cloud services landscape overall," said Carl Olofson, research vice president, Data Management Software, IDC.

Familiar Experience for Azure Users Combined with an Oracle Managed Service

With the new Oracle Database Service for Microsoft Azure, in just a few clicks users can connect their Azure subscriptions to their OCI tenancy. The service automatically configures everything required to link the two cloud environments and federates Azure Active Directory identities, making it easy for Azure customers to use the service. It also provides a familiar dashboard for Oracle Database Services on OCI using Azure terminology and monitoring with Azure Application Insights.

"Many of our mission-critical workloads are running Oracle databases on-premises at massive scale. As we move these workloads to the cloud, Oracle Database Service for Azure enables us to modernize these Oracle databases to services such as Autonomous Database in OCI while leveraging Microsoft Azure for the application tier," said Jeremy Legg, chief technology officer, AT&T. Watch the video.

"Multicloud architectures enable us to choose the best cloud provider for each workload based on capabilities, performance, and price. The OCI and Azure partnership integrates the capabilities of two major cloud providers, including the Oracle Database services in OCI and Azure's application development capabilities," said Naveen Manga, chief technology officer, Marriott International. Watch the video.

"Oracle Database Service for Microsoft Azure has simplified the use of a multicloud environment for data analytics. We were able to easily ingest large volumes of data hosted by Oracle Exadata Database Service on OCI to Azure Data Factory where we are using Azure Synapse for analysis," said Jane Zhu, senior vice president and chief information officer, Corporate Operations, Veritas.

"Oracle Database Service for Microsoft Azure simplifies our multicloud approach. We're going to be able to leverage the best of Oracle databases in Azure, and we are going to be able to keep our infrastructure in Azure. This is a great opportunity to have the best of the two worlds that eases our migration to the cloud and improves the skills of our people in IT," said David Plaza, chief information officer, SGS. Watch the video.

Additional Resources

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

About Microsoft

Microsoft (Nasdaq "MSFT" @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

Trademarks

Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

Contact Info

Carolin Bachmann
Oracle PR
+1.415.622.8466
carolin.bachmann@oracle.com

Microsoft Media Relations
WE Communications for Microsoft
+1 425 638 7777
rapidresponse@we-worldwide.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-microsoft-announce-availability-of-oracle-database-service-for-microsoft-azure-301589773.html

SOURCE Oracle

Wed, 20 Jul 2022 00:18:00 -0500 en-CA text/html https://ca.finance.yahoo.com/news/oracle-microsoft-announce-availability-oracle-121500988.html
VCS-322 exam dump and training guide direct download
Training Exams List